[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Genmab A/S (GNMSF)

Genmab A/S (GNMSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmab A/S CARL JACOBSENS VEJ 30 VALBY G7 2500 DNK

www.genmab.com Employees: 3,029 P: 45-7020-2728

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Key Statistics

Overview:

Market Capitalization, $K 20,810,656
Enterprise Value, $K 24,369,656
Shares Outstanding, K 61,570
Float, K 60,622
% Float 98.46%
Short Interest, K 199
Short Float 0.32%
Days to Cover 32.61
Short Volume Ratio 0.51
% of Insider Shareholders 1.54%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 3,720 M
Annual Net Income, $ 963,000 K
Last Quarter Sales, $ 1,155 M
Last Quarter Net Income, $ 303,000 K
EBIT, $ 1,257 M
EBITDA, $ 1,328 M

Growth:

1-Year Return 39.76%
3-Year Return -6.37%
5-Year Return -27.29%
5-Year Revenue Growth 140.15%
5-Year Earnings Growth 37.48%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 5.42 on 08/06/26
Next Earnings Date 11/05/26
Earnings Per Share ttm 13.97
EPS Growth vs. Prev Qtr 251.95%
EPS Growth vs. Prev Year 0.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

GNMSF Ratios

Ratio
Price/Earnings ttm 24.12
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 14.89%
Return-on-Assets % 7.73%
Profit Margin % 25.89%
Debt/Equity 0.86
Price/Sales 5.58
Price/Cash Flow 21.60
Price/Book 3.49
Book Value/Share 96.75
Interest Coverage 5.48
60-Month Beta 0.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.